Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Investor Presentation just updated

<< Previous

Bullboard Posts

Next >>

Comment by askretkaon Nov 17, 2022 8:07pm

273 Views

Post# 35109012

RE:RE:RE:Investor Presentation just updated

If you look at older Douglas Loe reports he's expecting Earnings for ONC of over 6$ per share on Royalties from Breast Cancer, Pancreatic Cancer and Myeloma in 2030. ------ At 20x earnings that's a 120$ a share stock in 2030. ---------- That includes nothing for CAR-T and nothing for China Breast Cancer deal so far. ----------- I don't think Big Pharma will want to pay those Royalties they'd rather own rights to Pelareorep via buyout. My 2 cents worth anyway.

<< Previous

Bullboard Posts

Next >>

Who, why, and what of the great "Crypto Surge"